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ABSTRACT 
OBJECTIVE: To analyze the prevalence of medicine use by the Brazilian population and its 
distribution according to sociodemographic factors.
METHODS: Study using data from the Pesquisa Nacional de Acesso, Utilização e Promoção do 
Uso Racional de Medicamentos (PNAUM – National Survey on Access, Use and Promotion of 
Rational Use of Medicines), a nationwide household survey of a representative sample of the 
Brazilian urban population. The data were collected between September 2013 and February 2014. 
The overall use of medicines, defined as the use of any medicine, use of medicines for treating 
chronic medical conditions and for acute health conditions, was evaluated. The independent 
variables included gender, age group, socioeconomic position, and region of Brazil. Analyzes 
included prevalence calculations, 95% confidence intervals (95%CI) and Pearson Chi-square 
tests to evaluate the differences between groups, considering a 5% level of significance.
RESULTS: The prevalence of medicines use was 50.7% (95%CI 49.3–52.2), with 39.3% 
(95%CI 37.5–41.1) accounting for men and 61.0% (95%CI 59.3–62.6) for women. Medicines use 
was observed to increase with increasing age, except among children within the zero to four 
years age group. The lowest prevalence for medicines use was found among those with a low 
socioeconomic position and those who reside in the North region of Brazil. The prevalence 
of medicine use to treat chronic diseases was 24.3% (95%CI 23.3–25.4), whereas it was 33.7% 
(95%CI 32.1–35.4) for treating acute diseases.
CONCLUSIONS: We found extensive variability in the prevalence of medicines use across 
regions of Brazil. The poorest regions (North, Northeast, and Midwest) have a lower prevalence 
of medicines use to treat chronic diseases, indicating the need to minimize inequalities in access 
to medicines within the country.
DESCRIPTORS: Drug Utilization. Socioeconomic Factors. Health Inequalities. Health Surveys. 
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INTRODUCTION
The last century has seen medicines become highly relevant social assets to humanity as a 
whole, with them contributing towards improved quality of life and increased life expectancy 
for people2. It is reasonable to consider medicines as an indispensable resource for most 
therapeutic plans16. 
There are important differences in determining the profile of medicine use when evaluating 
samples from institutions (hospitals, primary healthcare units, schools), samples from sick 
individuals and population-based samples5. Population-based samples can provide a true 
picture of the population medicine use profile; this scenario contributes to estimate the 
need for medicines as health resources, which is essential information for directing public 
policy and new research in the area3,5,25. 
There have been international studies to evaluate medicines use that showed the overall 
prevalence of use (any medicine) ranging from 49.6% (Cuba) to 74.7% (Germany). The prevalence 
of medicine use in two Spanish communities were found to be 65.1% and 67.0%, respectively, 
utilization being higher among women and increasing in frequency along with age9,22. 
In Brazil, studies on medicine utilization found wide variations in prevalence, with values 
raging between 49.0% and 56.9%. These results were identified  respectively by Carvalho et 
al.10, among individuals aged 18 years or more, and by a study developed by the Conselho 
Nacional de Secretários de Saúde (Brazilian National Council of Health Secretaries)11, among 
individuals aged 16 years or more. The latter study found that the prevalence of use in different 
geographic regions in Brazil was highest in the South (62.3%) and Southeast (62.2%), followed 
by the Midwest (50.5%), Northeast (50.2%) and North regions (43.1%).
Other studies carried out in Brazilian cities and the Federal District, using different recall 
periods and age groups, showed a high variability in the prevalence of medicines use by the 
populations under investigation (35.7% to 76.5%). In Brasilia (FD), the prevalence was 35.7%14, 
in Florianopolis (SC), 76.5%8, in Campinas (SP), 48.5%12, in Fortaleza (CE), 49.7%2, and in Pelotas 
(RS), 65.9%4. Medicines use was higher among women and increases according to age and 
socioeconomic status during the studies conducted in Campinas, Fortaleza and Pelotas2,4,12. 
In-depth health surveys have not yet been conducted in Brazil to evaluate medicines use, due 
to the fact that the extensive detail the theme requires would absorb much of the research 
itself. Pesquisa Nacional de Acesso, Utilização e Promoção do Uso Racional de Medicamentos 
(PNAUM – National Survey on Access, Use and Promotion of Rational Use of Medicines) 
was specifically designed to investigate the use of medicines in a representative sample of 
the Brazilian population. 
The purpose of this study was to analyze the prevalence of medicines use in Brazilian 
geographical regions, considering the use of any medicine and those used specifically for 
acute or chronic diseases, according to sociodemographic characteristics of the population.
METHODS
The PNAUM was a population-based cross-sectional study, with the data being collected 
between September 2013 and February 2014 in households in Brazilian cities. Face-to-face 
interviews were conducted in these households, and the data were recorded using tablets 
and software that had been specifically developed for applying questionnaires. 
The study population was made up of residents permanently residing in private households 
within the Brazilian territory’s urban area, and included individuals from all age groups. 
Sample size calculations considered eight demographic aspects (different genders and ages) 
that were repeated in each of Brazil’s major geographic regions, resulting in 40 sampling 
domains. A sample size of 960 interviews per sampling domain was the result, totaling 
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38,400 interviews. The sample was selected based on three stages: municipality (primary unit), 
census sector and household. Participants were selected from households, based on the 
expected proportion of each age group and gender to compose the final sample. The sampling 
process was complex and resulted in a sample that ensured national representation for the 
five Brazilian regions stratified by sex and age groups. Details regarding the sampling and 
data collection logistics are described in the PNAUM methodological article18. 
The questionnaires were developed by researchers from seven universities in Brazil, having 
been standardized and tested previous to their implementation. 
Medicine use was investigated based on three perspectives. The first sought to find 
information regarding the current use of medicines for chronic diseases. This involved 
information on previous diagnosis and medical recommendation to use medicines to treat 
specific chronic diseases (hypertension, diabetes, heart disease, high cholesterol, a history 
of stroke, chronic respiratory diseases, arthritis, arthrosis or rheumatism, and depression). 
Other chronic diseases lasting more than six months were also investigated. 
The second perspective aimed to evaluate medicines use for any possible health problems, 
generally characterized by signs, symptoms and acute conditions treated with medicines. 
Investigating these cases involved inquiring into medicines use 15 days prior to the research 
for specific health issues or groups of medicines (infection, sleeping medicines, nerves, 
stomach or bowel problems, pain, fever, flu, colds or allergic rhinitis, vitamin, mineral 
supplement, appetite stimulant or tonic) and any other medicines that had been unreported. 
The third perspective separately investigated current contraceptive use, depending on the 
characteristics of this group of medicines that is unrelated to disease and has everything 
to do with contraception. The complete questionnaire can be seen on the PNAUM survey 
website (http://www.ufrgs.br/pnaum). 
The analyzed outcomes were as follows: 1) overall prevalence of medicines use (use of at least 
one medicine for chronic disease, eventual or contraceptive use); 2) prevalence of medicines 
use for chronic diseases (use of at least one medicine for chronic diseases); 3) prevalence 
of medicines use for eventual or acute diseases (use of at least one medicine to treat acute 
signs, symptoms or conditions).
The independent variables under analysis were: age group (0-4; 5-9; 10-19; 20-29 30-39; 40;-49; 
50-59 60-69; 70;-79; 80 years old or more); economic classification (A/B; C; D; E), according 
to the Brazilian Economic Classification Criterion of the Associação Brasileira de Empresas 
de Pesquisa (CCEB 2013/ABEP – http://www.abep.org/), and residential geographical region 
(North; Northeast; Southeast; South, Midwest). 
Analyses for this article were performed using the total sample and the sample stratified by 
gender. All analyses were conducted with Stata version 12 (StataCorp LP, College Station, 
Texas, EUA) statistical software, using the set of svy commands designed to analyze complex 
samples. The analyses guaranteed the required weighting by contemplating the characteristics 
of the sample design that used different sampling fractions and post-stratification weights 
to correct the response rate flaw. The calculated percentages were weighted to adjust the 
PNAUM sample’s demographic distribution to the Brazil’s population.
In addition to the prevalence estimates, 95% confidence intervals (95%CI) were calculated 
and the Pearson’s Chi-square test was applied to assess the statistical significance of the 
differences among the groups, considering a 5% level of significance.
The study’s design was submitted and approved by the Comissão Nacional de Ética em Pesquisa 
(CONEP – Brazilian National Commission for Ethics in Research). All the interviews were 
conducted after the respondent or his/her legal guardian (in the case of individuals under 
18 years old or those unable to answer the questions themselves) had signed a free prior 
and informed consent term.
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RESULTS
The study sample included 41,433 individuals with a distribution that was comparable with 
that from the 2010 Brazilian Population Census (percentages weighted by sampling weights). 
The response rates from households were around 50.0%, which includes the losses from 
the households that were not visited. The response rates from the individuals were around 
90.0%. The methodological article includes a detailed table of the response rates by gender 
and age group as well as by geographical region18.
The weighted estimates indicated that 52.8% of the respondents were female, 22.3% of whom 
belonged to economic classes A or B, 57.1% were adults aged between 20 and 59 years, and 
with 45.9% residing in the Southeast region of Brazil (Table 1).
The overall prevalence of medicines use was 50.7% (95%CI 49.3–52.2), with 39.3% 
(95%CI 37.5–41.1) being males and 61.0% (95%CI 59.3–62.6) females. After the sample was 
stratified by age groups, there was an observed increase in the prevalence of use along with 
increasing age, the exception being the first age group (zero to four years), which is about 
70.0% higher than the following group ( five to nine years). The largest use of medicines by 
females begins from the 10-19 years age group (Table 1). Figure 1 shows the extent of the 
differences for each age group. Women use more than twice as many medicines as men 
between the ages of 20 and 29.
The smallest prevalence of use was in the group with the smallest economic classification 
(class E) in both gender groups. The groups with the highest purchasing power used about 
20.0% more medicines than those with the lowest economic classification (Table 1).
Table 1. Distribution of the sample and prevalencea of medicines use in Brazil, according to sociodemographic characteristics. PNAUM, 
Brazil, 2014. (N = 41,433)
Sociodemographic characteristic
Sample
Prevalence of medicines use
All Male Female
% Prevalence 95%CI Prevalence 95%CI Prevalence 95%CI
Age groupb < 0.001c < 0.001 < 0.001
0-4 6.2 42.0 39.5–44.6 42.6 39.5–45.7 41.4 38.6–44.3
5-9 7.5 25.3 22.0–28.6 26.7 21.6–31.8 23.9 19.4–28.5
10-19 16.0 30.6 27.9–33.3 24.5 20.7–28.2 36.5 32.7–40.4
20-29 16.5 48.0 45.4–50.6 31.4 26.8–35.9 64.4 62.0–66.8
30-39 15.3 50.6 47.9–53.2 34.8 30.3–39.3 64.5 61.8–67.3
40-49 13.8 54.1 52.0–56.2 39.0 36.6–41.4 67.5 65.3–69.7
50-59 11.5 64.7 62.5–66.8 50.3 47.0–53.5 76.1 74.0–78.2
60-69 6.9 77.0 75.3–78.7 68.3 65.7–70.9 83.8 81.9–85.6
70-79 4.3 85.8 84.0–87.5 79.8 76.1–83.4 89.9 88.2–91.6
≥ 80 2.0 88.6 86.1–91.1 85.2 81.6–88.9 90.9 87.6–94.2
Economic classificationd 0.027 0.423 0.015
A/B 22.3 51.9 49.2–54.5 40.7 37.0–44.4 62.5 59.9–65.1
C 55.3 51.1 49.4–52.8 39.2 37.2–41.2 61.5 59.5–63.5
D 17.7 50.1 47.5–52.8 39.1 35.7–42.6 59.2 56.2–62.2
E 4.6 43.5 38.2–48.8 34.6 27.6–41.6 53.2 47.0–59.3
Region 0.001 0.057 < 0.001
North 7.5 42.4 38.0–46.7 35.7 31.7–39.6 48.6 43.1–54.1
Northeast 24.3 53.4 51.2–55.7 42.7 39.7–45.6 62.6 60.1–65.0
Southeast 45.9 50.8 48.1–53.5 39.1 35.7–42.4 61.3 58.3–64.3
South 14.3 49.8 46.8–52.9 36.5 32.9–40.1 61.8 59.0–64.6 
Midwest 7.9 51.8 49.2–54.4 39.5 36.2–42.7 63.9 60.7–67.0
Total 100 50.7 49.3–52.2 39.3 37.5–41.1 61.0 59.3–62.6
a Percentages adjusted by sample weights and post-stratification according to age and gender. Weighted sample distribution by gender: 47.2% (male) and 
52.8% (female). 
b In years.
c Pearson’s Chi-square test.
d The economic classification variable according to the Brazilian Economic Classification Criterion of the Associação Brasileira de Empresas de Pesquisa 
(http://www.abep.org) had 77 ‘missing’.
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The geographical region which had highest prevalence of medicines use was the Northeast 
(male) and their prevalence was statistically higher than those observed in the North. 
The lowest prevalence occurred in the North region and was statistically lower than those 
observed in the other regions in the female gender (Table 1).
Table 2 shows the results related to the treatment of chronic diseases. The prevalence of 
medicines use for chronic diseases was 24.3% (95%CI 23.3–25.4): 18.7% (95%CI 17.6–19.9) for 
males and 29.4% (95%CI 28.1–30.7) for females. Considering the total sample, the prevalence 
increased with age – the oldest age group (80 years or more) used 14 times more medicines 
than the youngest age group (0-4 years). The prevalence increased from the 20 to 29 years age 
group among males, while the growth begins in the 10 to 19 years age group among females.
Table 2. Prevalencea of medicines use to treat chronic diseases in Brazil, according to sociodemographic characteristics. PNAUM, Brazil, 
2014. (N = 41,433)
Sociodemographic 
characteristic
Prevalence of medicines use to treat chronic diseases
All Male Female
Prevalence 95%CI Prevalence 95%CI Prevalence 95%CI
Age groupb < 0.001c < 0.001 < 0.001
0-4 5.7 4.8–6.5 6.4 5.2–7.5 5.0 3.8–6.1
5-9 5.2 3.6–6.8 6.0 3.4–8.5 4.5 2.3–6.6
10-19 5.3 4.1–6.5 4.9 3.2–6.5 5.7 4.0–7.4
20-29 7.5 6.1–8.9 5.8 3.7–7.9 9.2 7.5–10.8
30-39 14.9 13.2–16.5 11.2 8.5–13.9 18.1 16.2–19.9
40-49 28.9 27.4–30.4 20.5 18.7–22.4 36.4 34.3–38.5
50-59 49.9 48.0–51.8 36.4 33.7–39.1 60.5 58.0–63.0
60-69 66.2 64.2–68.1 56.7 53.7–59.7 73.5 71.3–75.7
70-79 78.5 76.4–80.6 71.6 67.8–75.5 83.2 81.1–85.4
≥ 80 79.7 75.6–83.8 73.4 70.7–80.0 82.7 76.7–88.6
Economic classificationd 0.011 0.033 0.038
A/B 26.5 24.6–28.4 21.0 18.6–23.4 31.8 29.6–34.1
C 24.2 23.0–25.4 18.6 17.2–20.0 29.1 27.6–30.6
D 22.4 20.6–24.3 16.4 14.4–18.4 27.4 24.9–29.9
E 23.1 19.6–26.6 18.2 13.7–22.6 28.5 23.8–33.3
Region < 0.001 < 0.001 < 0.001
North 14.0 12.2–15.7 11.6 9.7–13.5 16.1 14.0–18.3
Northeast 20.5 18.9–22.1 15.4 13.6–17.1 24.8 22.7–27.0
Southeast 27.5 25.7–29.4 21.4 19.3–23.5 33.0 30.8–35.3
South 26.7 24.5–28.9 19.9 17.6–22.3 32.8 30.4–35.3
Midwest 23.2 21.4–25.1 18.0 15.8–20.2 28.4 26.4–30.3
Total 24.3 23.3–25.4 18.7 17.6–19.9 29.4 28.1–30.7
a Percentages adjusted by sample weights and post-stratification according to age and gender. 
b In years.
c Pearson’s Chi-square test.
d The economic classification variable according to the Brazilian Economic Classification Criterion of the Associação Brasileira de Empresas de Pesquisa 
(http://www.abep.org) had 77 ‘missing’.
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Figure 1. Prevalence of overall medicines use in Brazil according to gender and age group. The values 
represent the percentage difference in medicines use by women compared to men. PNAUM, Brazil, 2014. 
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In regards to economic classification, the highest prevalence for medicines use was 
found in groups with the highest economic classification (A/B), and differences in 
which were statistically significant in relation to economic classification D in males. 
The prevalence of medicines use for treating chronic diseases was slightly higher in 
class E (poorest group) compared with class D (no statistical differences). The highest 
prevalence of medicines use for chronic diseases were found in the Southeast and South, 
with the entire sample showing significant statistical differences compared with the 
North and Northeast regions (Table 2).
Table 3 only shows the medicines used to treat acute health problems, which characterize 
eventual use of medicines. The prevalence of medicines use for these health problems was 
33.7% (95%CI 32.1–35.4): 27.2% (95%CI 25.4–29.0) for males and 39.6% (95%CI 37.6–41.5) 
for females. The usage patterns for the total sample indicate an increasing trend from the 
five to nine years age group up to the 80 years or more age group. In the zero to four years 
age group, the prevalence of use of eventual medicines was the same as the adults above 
30 years age group. The oldest age group (80 years or more) in males used two times more 
eventual medicines than the children in the five to nine years age group; this ratio was 
2.5 times higher in females using the same comparison basis. There were no differences 
found in the use of such medicines by economic classification, despite their prevalence 
being approximately 20.0% higher in class A/B compared with class E (Table 3).
In regards to the geographical regions, the highest prevalence of medicines use was in the 
Northeast (with a statistically significant difference compared with the North, East and 
South) and the lowest in the South (with a statistically significant difference compared with 
the Northeast and Midwest regions) (Table 3). 
Table 3. Prevalencea of medicines use to treat acute diseases in Brazil, according to sociodemographic characteristics. PNAUM, Brazil, 
2014. (N = 41,433)
Variable
Prevalence of medicines use to treat acute diseases
All Male Female
Prevalence 95%CI Prevalence 95%CI Prevalence 95%CI
Age groupb < 0.001c < 0.001 < 0.001
0-4 39.0 36.5–41.6 39.4 36.3–42.5 38.6 35.9–41.4
5-9 21.8 18.5–25.0 21.8 17.9–27.7 20.8 16.5–25.1
10-19 24.6 22.0–27.1 20.9 17.2–24.5 28.1 24.4–31.8
20-29 32.3 29.4–35.3 26.9 22.6–31.3 37.7 34.6–40.7
30-39 35.3 32.5–38.1 27.9 23.6–32.1 41.8 38.9–44.7
40-49 36.2 33.8–38.5 25.6 23.3–27.9 45.6 42.8–48.4
50-59 37.6 35.0–40.1 25.5 22.4–28.6 47.2 44.0–50.3
60-69 41.1 38.5–43.8 33.3 30.1–36.4 47.2 44.0–50.5
70-79 44.2 41.3–47.1 33.4 29.2–37.6 51.6 48.1–55.1
≥ 80 48.3 44.2–52.5 44.5 38.5–50.5 51.0 46.0–55.9
Economic classificationd 0.097 0.314 0.263
A/B 34.0 31.3–36.6 27.7 24.2–31.1 40.0 36.9–43.0
C 33.8 31.9–35.7 27.0 24.9–29.0 39.8 37.6–42.0
D 34.7 31.9–37.5 28.8 25.1–32.5 39.6 36.6–42.6
E 28.1 23.9–32.3 22.3 16.8–27.9 34.3 29.6–39.0
Region < 0.001 < 0.001 < 0.001
North 31.6 27.6–35.6 27.5 24.0–31.0 35.4 30.2–40.6
Northeast 40.2 37.8–42.7 33.6 30.4–36.7 45.9 43.3–48.5
Southeast 31.7 28.6–34.8 25.0 21.8–28.2 37.7 34.0–41.5
South 29.4 26.8–32.1 23.2 20.2–26.1 35.1 32.4–37.7
Midwest 35.4 32.6–38.2 28.3 24.8–31.7 42.4 39.2–45.7
Total 33.7 32.1–35.4 27.2 25.4–29.0 39.6 37.6–41.5
a Percentages adjusted by sample weights and post-stratification according to age and gender.
b In years.
c Pearson’s Chi-square test.
d The economic classification variable according to the Brazilian Economic Classification Criterion of the Associação Brasileira de Empresas de Pesquisa 
(http://www.abep.org) had 77 ‘missing’.
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Figure 2 shows a comparison between the prevalence of overall usage, use of medicines for 
chronic diseases and use of medicines for acute conditions of each region in relation to Brazil 
as a whole. The North region had the most significant percentage differences in regards to 
overall use (-16.0%) and medicines for chronic diseases (-42.0%), these being smaller than the 
prevalence for such in Brazil. The Northeast region had the highest percentage for eventual 
medicines use (+19.0%), being greater than the national prevalence.
DISCUSSION
Studies on medicines use can be conducted using routine or survey databases. Developed 
countries usually integrate data on medicines prescription and distribution, which generates 
databases that include information regarding the patient, medicines recommendation, 
dosage etc23. In Brazil, we have only consolidated data from industry based on retail sales. 
Thus, surveys are conducted with the objective of obtaining data about who used medicines, 
what was used and whether or not it was possible to get the necessary medicines. 
The PNAUM survey was the first national study in Brazil that was specifically designed to 
evaluate medicines use in the five geographic regions of Brazil, which resulted in detailed 
information on all medicines used to treat chronic diseases, acute health situations 
and contraceptives. Among the Brazilian studies that included questions regarding 
medicines, the following are highlighted: the Pesquisa Nacional por Amostra de Domicílios 
(PNAD – National Household Sample Survey – http://www.ibge.gov.br), which records the 
continuous medicines use related to the last time the health services were used; the Pesquisa 
de Orçamentos Familiares (POF – Brazilian Household Budget Survey – http://www.ibge.gov.
br) that records expenditure on medicines obtained over the last 30 days, purchase location 
and payment type; Pesquisa Nacional de Demografia e Saúde (PNDS – Brazilian National 
Demographic and Health Survey – http://www.ibge.gov.br); and the World Health Survey 
(WHS)24. The latter two used a similar strategy, in which they ask about prescription, use, 
sources to obtain medicines, primarily based on a list of chronic diseases. 
Considering the overall prevalence of any type of medicines, slightly more than half the 
population used some kind of medicines within the periods investigated during the research, the 
results showing that use by women was 55.0% greater than that of men. The overall prevalence 
estimate is in line with other studies, which is true even when those with a smaller sample 
size are considered2,4,10,12,14. The greater use of medicines by women is also described in various 
national and international studies20. This difference is attributed to gender, in addition to the 
exclusive use of contraceptives, to factors related to increased use of health services and health 
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Figure 2. Prevalence of medicines use according to the type of use in the different regions of Brazil. The values represent the percentage 
difference between the prevalence of use in each region compared with the prevalence in Brazil. PNAUM, Brazil, 2014.
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care21, which begin during adolescence, due to complications related to the menstrual cycle 
and pregnancy. This is a period in which the differences start and continue to grow until the 
end of adulthood. Among the elderly, women are still the greatest medicines users, but the 
differences are smaller, a fact that is consistent with the literature13,20. 
Medicines use by age group reflects the population’s profile of morbidities, starting with a high 
percentage for the use of eventual medicines in early childhood followed by a reduction and 
subsequent gradual increase along with increasing age, and with the percentage of medicines use 
to treat chronic diseases. The prevalence of medicines use is close to 90.0% in the 80 years or more 
age group. This result is in line with those from other studies, which indicate the same trend4 and 
show the impact of demographic and epidemiological transition in the use of medicines by the 
Brazilian population. In light of this scenario, efforts in terms of pharmaceutical service policy 
should be directed towards care strategies to guide these patients within the health care system, 
the aim being to guarantee access to essential medicines, to promote their rational use and to 
improve adherence to treatment. This study showed a higher medicines use by people belonging 
to the highest economic classification (A/B). Data from the literature consistently indicate this 
same result2,4,10,12, since medicines use depends on their access and this can be conditioned by 
the purchasing power of individuals when drugs are not available free of charge7. 
We found a wide variability in the overall prevalence of medicines use in the different regions 
in Brazil. The lowest prevalence of medicines use is found in the North region, which is 
probably due to greater dependence and inefficiency of the public system regarding access to 
medicines, less medical diagnoses as a result of difficulties in accessing medical services, and 
even because of there likely being fewer locations to obtain medicines in the private sector 
than in the other Brazilian regions1. These variations are even sharper when the medicines are 
stratified by disease groups. According to the Brazilian Institute of Geography and Statistics 
(IBGE), the poorest regions (North, Northeast and Midwest) have the lowest prevalence of 
medicines use for chronic diseases compared with Brazil as a whole. On the other hand, the 
South and Southeast regions have the greatest prevalence of medicines use for these diseases. 
Being able to use medicines to treat chronic diseases can be considered a proxy of quality health 
care, since these diseases depend on a previous diagnosis for its control and evolution with 
the use of medicines17. At the same time, the Northeast and Midwest regions have the largest 
percentages of medicines use for eventual or acute diseases, which may be associated with 
self-medication and the pursuit of resolving acute health problems caused by medicines use6. 
When we only consider treating chronic illnesses, the prevalence of medicines use is observed to 
be less than 10.0% up until 29 years of age, regardless of gender. From 30 years of age onwards, we 
found an increase in medicines use for these diseases. When we consider the entire population, 
the oldest age group (80 years or more) uses 5.3 times more medicines than the 30-39 years age 
group.  When we only consider the male gender, this increase is 6.6 times, and only 4.6 times 
for women. This behavior based on age has already been covered in the literature19. 
In relation to the treatment of acute diseases, the prevalence is high from childhood onwards, 
which is true for both boys and girls. The increases in the prevalence for males are 1.95 times 
greater in the 80 years or more age group compared with the five to nine years age group. 
This increase is 2.5 times higher for the female gender, indicating a greater stability in the 
use prevalence of these medicines compared with those used to treat chronic diseases.
It is possible to highlight the national and regional representation as a strong point of this 
study, which has allowed an overview of the overall use of medicines in Brazil to be created 
for the first time. Comparisons made by gender, age and economic class showed similar 
results regarding medicines use between the PNAUM survey and previous studies, and also 
built upon the differential characteristics observed in the patterns for medicines use for 
chronic and acute diseases in Brazil’s geographical regions.
At the same time, it is important to highlight that there are some inherent limitations to a survey 
of such magnitude. As the information depends on reports from respondents or their legal 
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guardians, in the case of individuals aged less than 18 years old or persons unable to answer 
their own questionnaires, it is possible the existence of some degree of response error regarding 
which medicines were used. The periods adopted to investigate medicines use should also be 
considered. Current use was investigated for continuous use of medicines and contraceptives, 
and a 15-day recall period was used for medicines used to treat eventual health issues. Despite 
this procedure not being unusual in the literature5, comparisons with other studies should always 
consider that the prevalence may vary according to the investigation period for medicines use5. 
Evaluating the Brazilian population’s profile for medicines use by age groups, gender and 
medicines type ( for acute diseases or chronic diseases) made it possible to characterize 
the differences between the groups and tendencies among the geographic regions of Brazil. 
The Brazilian Government has invested in strategies to improve access to medicines and 
enhance the quality of pharmaceutical services with initiatives such as regulating generic 
medicines (Law 9,787, February 10th, 1999), the Brazilian Farmácia Popular (Popular Pharmacy 
Program) (Decree 5,090, May 20th, 2004), the QualifarSUS (Ordinance GM/MS 1,214), among 
others. We hope that the results from this study can help guide the Brazilian government in 
regards to pharmaceutical services, the aim being to further improve the population’s access 
to essential medicines and ensure their rational use. The areas that were identified to have a 
lesser prevalence of medicines use to treat chronic diseases, such as the North and Northeast 
regions, should be prioritized to minimize the inequalities in terms of access to medicines.
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